| Balancing the needs of the many and the few: where next for adult asthma guidelines? | Lancet Respiratory Medicine | 3 days | save |  |  |  |  |
| Correction to Lancet Respir Med 2021; published online Feb 10. https://doiorg/10.1016/S2213-2600(20)30510-5 | Lancet Respiratory Medicine | 4 days | save | | | | |
| When should the UK lift its lockdown? | Lancet Respiratory Medicine | 8 days | save | | | | |
| Delayed-onset myocarditis following COVID-19 | Lancet Respiratory Medicine | 8 days | save | | | | |
| Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study | Lancet Respiratory Medicine | 10 days | save | | | | |
| Into the abyss | Lancet Respiratory Medicine | 10 days | save | | | | |
| Separation—a letter to my child | Lancet Respiratory Medicine | 10 days | save | | | | |
| The Troublemaker | Lancet Respiratory Medicine | 10 days | save | | | | |
| Correction to Lancet Respir Med 2021; 9: 85–95 | Lancet Respiratory Medicine | 11 days | save | | | | |
| Correction to Lancet Respir Med 2021; published online Jan 28. https://doi.org/10.1016/ | Lancet Respiratory Medicine | 11 days | save | | | | |
| Trends in COVID-19-related in-hospital mortality: lessons learned from nationwide samples | Lancet Respiratory Medicine | 12 days | save | | | | |
| Patient factors and temporal trends associated with COVID-19 in-hospital mortality in England: an observational study using administrative data | Lancet Respiratory Medicine | 12 days | save | | | | |
| COVID-19 survivor experiencing long-term symptoms | Lancet Respiratory Medicine | 15 days | save | | | | |
| COVID-19 in the Caribbean | Lancet Respiratory Medicine | 16 days | save | | | | |
| Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study | Lancet Respiratory Medicine | 17 days | save | | | | |
| Bearing witness in the time of COVID | Lancet Respiratory Medicine | 17 days | save | | | | |
| A tribute to the gang | Lancet Respiratory Medicine | 17 days | save | | | | |
| Oxygen supplies and COVID-19 mortality in Africa | Lancet Respiratory Medicine | 17 days | save | | | | |
| How could we forget? | Lancet Respiratory Medicine | 17 days | save | | | | |
| Neutrophilic asthma: misconception or misnomer? | Lancet Respiratory Medicine | 18 days | save | | | | |
| Correction to Lancet Respir Med 2020; 8: 873–84 | Lancet Respiratory Medicine | 19 days | save | | | | |
| Algeria's response to COVID-19: an ongoing journey | Lancet Respiratory Medicine | 19 days | save | | | | |
| Provision of holistic care after severe COVID-19 pneumonia – Authors' reply | Lancet Respiratory Medicine | 22 days | save | | | | |
| Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial | Lancet Respiratory Medicine | 22 days | save | | | | |
| COVID-19: a heavy toll on health-care workers | Lancet Respiratory Medicine | 22 days | save | | | | |
| Yemen: Coronavirus in a War Zone | Lancet Respiratory Medicine | 22 days | save | | | | |
| Provision of holistic care after severe COVID-19 pneumonia | Lancet Respiratory Medicine | 22 days | save | | | | |
| COVID-19 vaccination in athletes: ready, set, go… | Lancet Respiratory Medicine | 22 days | save | | | | |
| Use of fibrinolytics and deoxyribonuclease in adult patients with pleural empyema: a consensus statement | Lancet Respiratory Medicine | 25 days | save | | | | |
| High oxygen flow rates with the UCL Ventura CPAP device – Authors' reply | Lancet Respiratory Medicine | 25 days | save | | | | |
| High oxygen flow rates with the UCL Ventura CPAP device | Lancet Respiratory Medicine | 25 days | save | | | | |
| Caution advised regarding lung recruitment before surfactant | Lancet Respiratory Medicine | 25 days | save | | | | |
| The Biden administration: changing the tide for health? | Lancet Respiratory Medicine | 26 days | save | | | | |
| Geography, generalisability, and susceptibility in clinical trials | Lancet Respiratory Medicine | 26 days | save | | | | |
| SARS-CoV-2 evolution and vaccines: cause for concern? | Lancet Respiratory Medicine | 27 days | save | | | | |
| Bronchial thermoplasty: 10 years and counting | Lancet Respiratory Medicine | 27 days | save | | | | |
| Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials | Lancet Respiratory Medicine | 27 days | save | | | | |
| Instrumental dead space in ventilator management | Lancet Respiratory Medicine | 27 days | save | | | | |
| Instrumental dead space in ventilator management – Authors' reply | Lancet Respiratory Medicine | 27 days | save | | | | |
| Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study | Lancet Respiratory Medicine | 27 days | save | | | | |
| Living with bronchiectasis during the COVID-19 pandemic | Lancet Respiratory Medicine | 27 days | save | | | | |
| Correction to Lancet Respir Med 2021; published online Jan 8. https://doi.org/10.1016/S2213-2600(20)30552-X | Lancet Respiratory Medicine | 31 days | save | | | | |
| Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial | Lancet Respiratory Medicine | 31 days | save | | | | |
| New and old treatments for malignant mesothelioma: not just immunotherapy | Lancet Respiratory Medicine | 31 days | save | | | | |
| Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial | Lancet Respiratory Medicine | 31 days | save | | | | |
| Correction to Lancet Respir Med 2020; published online Dec 22. https://doi.org/10.1016/S2213-2600(20)30414-8 | Lancet Respiratory Medicine | 33 days | save | | | | |
| Use of point-of-care testing for respiratory viruses in hospital | Lancet Respiratory Medicine | 36 days | save | | | | |
| Touch, and the absence of it | Lancet Respiratory Medicine | 36 days | save | | | | |
| Untouched | Lancet Respiratory Medicine | 36 days | save | | | | |
| Nebulised heparin for patients on ventilation: implications for COVID-19 pneumonia | Lancet Respiratory Medicine | 36 days | save | | | | |
| | 
report | next » |
| |
